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Abstract
Background: LDL-C, non-HDL-C and ApoB levels are inter-correlated and all predict risk of atherosclerotic
cardiovascular disease (ASCVD) in patients with type 2 diabetes mellitus (T2DM) and/or high TG. These levels are
lowered by extended-release niacin (ERN), and changes in the ratios of these levels may affect ASCVD risk. This
analysis examined the effects of extended-release niacin/laropiprant (ERN/LRPT) on the relationships between
apoB:LDL-C and apoB:non-HDL-C in patients with T2DM.
Methods: T2DM patients (n = 796) had LDL-C ≥1.55 and <2.97 mmol/L and TG <5.65 mmol/L following a 4-week,
lipid-modifying run-in (~78 % taking statins). ApoB:LDL-C and apoB:non-HDL-C correlations were assessed after
randomized (4:3), double-blind ERN/LRPT or placebo for 12 weeks. Pearson correlation coefficients between
apoB:LDL-C and apoB:non-HDL-C were computed and simple linear regression models were fitted for apoB:LDL-C and
apoB:non-HDL-C at baseline and Week 12, and the correlations between measured apoB and measured vs predicted
values of LDL-C and non-HDL-C were studied.
Results: LDL-C and especially non-HDL-C were well correlated with apoB at baseline, and treatment with ERN/LRPT
increased these correlations, especially between LDL-C and apoB. Despite the tighter correlations, many patients who
achieved non-HDL-C goal, and especially LDL-C goal, remained above apoB goal. There was a trend towards greater
increases in these correlations in the higher TG subgroup, non-significant possibly due to the small number of subjects.
Conclusions: ERN/LRPT treatment increased association of apoB with LDL-C and non-HDL-C in patients with T2DM.
Lowering LDL-C, non-HDL-C and apoB with niacin has the potential to reduce coronary risk in patients with T2DM.
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Highlights
 LDL-C, ApoB and non-HDL-C are markers of
coronary risk.
 Niacin reduces LDL-C, ApoB and non-HDL-C, with
or without concurrent statin treatment.
 Statins increase the strength of correlations of ApoB
with LDL-C and non-HDL-C.
 We studied the effects of niacin on these correlations
in patients with diabetes.
 Niacin also increased the strength of correlations of
ApoB with LDL-C and non-HDL-C.
Background
The prevalence of type 2 diabetes mellitus (T2DM) is
high. In 2010, an estimated 19.7 million Americans,
8.3 % of the adult population, had diagnosed T2DM [1].
An additional 8.2 million Americans had undiagnosed
T2DM, and 38.2 % had pre-diabetes, with abnormal fast-
ing glucose levels [1]. Patients with T2DM have a two- to
four-fold elevated risk of cardiovascular disease relative to
people without diabetes [2]. The dyslipidemia commonly
associated with T2DM is typified by elevated plasma tri-
glycerides (TG), low high-density lipoprotein cholesterol
(HDL-C) levels, and a preponderance of small, dense low-
density lipoprotein (LDL) particles [3].
Aggressive treatment of dyslipidemia is recommended
for patients with T2DM to reduce coronary heart disease
(CHD) risk, with the cornerstone of treatment being sta-
tin therapy. The Third Report of the National Cholesterol
Education Program Expert Panel on Detection, Evaluation,
and Treatment of High Blood Cholesterol in Adults
(NCEP ATP-III) suggested treatment to achieve a low-
density lipoprotein cholesterol (LDL-C) goal <2.59 mmol/L
and optionally <1.81 mmol/L, with corresponding goals for
non-high-density lipoprotein cholesterol (non-HDL-C) of
<3.36 mmol/L and <2.59 mmol/L, respectively, in patients
with the highest CHD risk [4–8]. In November 2013, the
American College of Cardiology and American Heart As-
sociation (ACC/AHA) released cholesterol guidelines
which did not endorse LDL-C and non-HDL-C treatment
goals [9], but this deletion has been rejected by several pro-
fessional national and international societies [10–12]. Fur-
ther, it is important to note that the NHLBI, which had
sponsored the lengthy data review and writing efforts
(completely independent of the ACC and AHA), decided
at the end of these processes that the resulting document
should be published simply as an “evidentiary review.” [13]
For this reason, it seems inappropriate that subsequent
cursory ACC/AHA review and approval of the NHLBI-
derived document be considered to have produced an offi-
cial US guideline. Thus, primary reliance on lipid goals
continues to be quite reasonable in clinical practice world-
wide. Finally, despite the fact that the main lipid guideline
emphasis traditionally has been on LDL-C, recent evidence
suggests that apolipoprotein (apo) B and non-HDL-C may
be better indicators of CHD risk, especially for patients
with T2DM and/or elevated TG [14–19].
Many patients with T2DM fail to reach their LDL-C,
non-HDL-C and apoB goals with statin therapy alone, in
which case combination therapy with other lipid-
modifying agents has been suggested [4, 5, 7, 8, 20]. Nia-
cin (nicotinic acid) is a lipid-modifying agent that lowers
LDL-C, apoB, non-HDL-C and TG levels and raises
HDL-C levels. The combination of statins and niacin pro-
duces additive and complementary effects on plasma
lipid/lipoprotein profiles. Previous clinical trials demon-
strated that niacin monotherapy reduced myocardial in-
farction at 5 years and cardiovascular mortality at 15 years
and, in combination with other lipid-modifying therapies
(statins, bile acid resins, or both), slowed progression/in-
duced regression of atherosclerotic plaque in patients with
cardiovascular disease [21–24]. In contrast, two recent
coronary outcomes trials failed to show that the addition
of extended release niacin (ERN) to statin monotherapy
further reduced cardiovascular events in patients with
established cardiovascular disease and low baseline LDL-
C levels, at least in the overall study populations [25, 26].
Subgroups with greater dyslipidemia, however, were noted
to benefit [26, 27]. Further, niacin remains a treatment op-
tion for certain disease states and specific patient groups
(e.g., statin-intolerant patients). Although niacin may not be
used extensively for the treatment of patients with T2DM
due to its tendency to worsen glycemic control, it is a rea-
sonable choice in T2DM patients who are statin-intolerant
and who have well-controlled plasma glucose levels.
Objective
Several studies have evaluated the effects of statin therapy
on the relationships (i.e., correlations and concordances)
between apoB:LDL-C and apoB:non-HDL-C [28–34], and
a recent study showed increasing strength in these corre-
lations following treatment with either ERN/LRPT, a sta-
tin, or their combination [35]. A recent meta-analysis of
statin trials found that on-treatment non-HDL-C and
apoB and LDL-C all predicted subsequent cardiovascular
events, and non-HDL-C was the best predictor among
them [14]. The effect of ERN (with or without laropipr-
ant) on apoB:LDL-C and apoB:non-HDL-C has not been
investigated to date in patients with T2DM.
This study is a post-hoc analysis of a previously pub-
lished clinical trial of ERN in combination with the flush-
ing pathway inhibitor, laropiprant (ERN/LRPT), which
significantly improved LDL-C, HDL-C and TG levels in
patients with T2DM [36]. Although ERN/LRPT has been
associated with a statistically significant increase in the
incidence of certain non-fatal serious adverse events [26]
and, therefore, has been withdrawn from the market and
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from further clinical development, laropiprant did not ap-
pear to alter the lipid effects of ERN. Thus, the data analyzed
in this study are considered relevant to ongoing clinical use
of ERN without laropiprant. This is the first study to com-
pare the effects of ERN/LRPT treatment versus placebo (at
12 weeks) on the relationships between apoB:LDL-C and
apoB:non-HDL-C in patients with T2DM. Given the known
influence of elevated TG levels on LDL particle composition,
these effects were further examined in patient subgroups
with higher or lower baseline TG value, using a clinically
meaningful cutoff of < and ≥2.26 mmol/L (200 mg/dL).
Methods
Study design
Post-hoc analysis was performed using data from a previ-
ously published, worldwide, multicenter (32 sites in the
United States and 62 international sites), double-blind,
randomized, placebo-controlled, parallel study of dyslipid-
emic patients with T2DM [36]. The study included a 4-
week lipid-modifying run-in period followed by a 36-week
double-blind treatment period. Complete details regarding
study design and patient-entry criteria are published else-
where (Protocol 069, Clinical Trials.gov: NCT00485758).
The study protocol was approved by the institutional re-
view boards at every study center and informed consent
was obtained from each subject before the initiation of
any study procedures. The study was conducted in ac-
cordance with the principles of Good Clinical Practice.
Patients
Eligible patients included men and women, ages 18 to
80 years, with a diagnosis of T2DM, taking a stable dose of
anti-diabetes medication for 3 months prior to study start.
Patients had LDL-C ≥1.55 and <2.97 mmol/L (greater than
or equal to 60 and less than 115 mg/dL) and TG
<5.65 mmol/L (less than 500 mg/dL) following a 4-week,
lipid-modifying run-in before the randomization visit. Ap-
proximately 78 % of patients were taking statins at baseline
and were permitted to continue those medications during
the study. Patients were excluded if they had the following
laboratory values at Visit 1: creatinine >2.0 mg/dL, creatine
kinase (CK) >2× the upper limit of normal (ULN), alanine
aminotransferase (ALT), aspartate aminotransferase (AST)
>1.5× ULN, or an abnormal thyroid stimulating hormone
level (>20 % above the ULN). Other exclusion criteria in-
cluded HbA1c >8.5 % at the screening visit or Visit 1, recent
(new) diagnosis of T2DM or initiation of anti-obesity ther-
apy within 3 months of Visit 1, use of systemic corticoste-
roids, and cyclical hormone contraceptives or other
intermittent hormone therapies in female patients. Permit-
ted lipid-altering therapies included dietary supplement
omega-3, HMG-CoA reductase inhibitors (“statins”), fibrates
(gemfibrozil, fenofibrate), ezetimibe, ezetimibe/simvastatin
combination tablet, and bile-acid sequestrants. Patients
taking therapies including niacin (>50 mg/day), Cholestin™,
and fibrates in combination with a statin were excluded.
Treatment
Patients were randomized 4:3 to ERN/LRPT 1 g/20 mg
(1 tablet) or placebo. After 4 weeks of double-blind
treatment, doses of active drug and placebo were dou-
bled, increasing the ERN/LRPT to 2 g/40 mg (2 tablets)
for the remainder of the study. No adjustments to back-
ground lipid-modifying regimens were made for the first
12 weeks of the study.
Clinical laboratory measurements
A Center for Disease Control-certified laboratory conducted
all clinical laboratory analyses using fasting blood samples.
Total cholesterol (TC) and TG were measured by enzymatic
methods. LDL-C was calculated by use of the Friedewald
equation [37]. Non-HDL-C was calculated by subtracting
HDL-C from TC values. ApoB was measured in whole
plasma by radioimmunoassay and nephelometry.
Statistical methods
This post-hoc analysis was performed on the subset of
patients (90 %; 716/796) who had a baseline and Week
12 or later value for all three variables of interest (i.e.,
apoB, LDL-C and non-HDL-C). The statistical methods
have been described previously in a similar analysis.35 In
brief, the analyses were performed in a modified intent-to-
treat population (n = 768) in the full analysis set (FAS)
population at Week 12, including all randomized patients
who had baseline and at least one post-Week 4 measure-
ments, and had received at least one dose of study medi-
cation. Subgroup analyses were performed for patients
defined by TG values, as follows: lower, <2.26 mmol/L
(less than 200 mg/dL, normal to borderline-high TG) and
higher, >2.26 mmol/L (hypertriglyceridemic).
An analysis of covariance (ANCOVA) model with
terms for treatment, country, gender, and corresponding
baseline lipid value as covariates was used to compare
least squares (LS) mean percent changes from baseline
in LDL-C, non-HDL-C and apoB between treatment
groups. The placebo-subtracted differences in LS mean
percent changes from baseline with 95 % confidence in-
tervals (CI) were estimated from the ANCOVA model.
To examine the linear relationships at baseline and
study end (week 12), simple linear regression models
with apoB as a response variable were fitted on the over-
all population who had paired baseline and post-baseline
values for apoB and LDL-C and apoB and non-HDL-C.
The predicted values of LDL-C and non-HDL-C for
known apoB values of 0.8 g/L or 0.9 g/L were calculated
from the models. Pearson correlation coefficients between
apoB:LDL-C and apoB:non-HDL-C were computed to in-
form the strength and direction of the correlations.
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The degree of concordance between apoB:LDL-C and
apoB:non-HDL-C were analyzed. Here, each patient was
categorized into a quintile for apoB, LDL-C and non-
HDL-C; those in the same quintile for the two parame-
ters being compared were considered concordant,
whereas those in different quintiles were considered dis-
cordant. The weighted kappa statistic was used to quan-
tify the overall degree of concordance between the
parameters. The concordance analyses were performed
for the overall population and within each treatment
group at baseline and endpoint; for each population, the
concordance analyses were examined by baseline TG
subgroup (i.e., < and ≥2.26 mmol/L, or 200 mg/dL).
Results
Approximately 78 % of patients were taking a statin at base-
line and continued to receive this treatment throughout the
study. The baseline demographic and lipid/lipoprotein
characteristics were generally well balanced between the
ERN/LRPT and placebo groups in the overall population
and within the patient subgroups defined by baseline TG
value (Table 1). As expected, patients with higher versus
lower baseline TG tended to have lower HDL-C levels and
higher apoB, non-HDL-C and total cholesterol levels at
baseline. Patients with higher versus lower baseline TG also
tended to have higher fasting plasma glucose and glycosyl-
ated hemoglobin levels at baseline. Within the higher base-
line TG subgroup, a slightly greater proportion of patients
in the ERN/LRPT group were not taking a lipid-lowering
medication at baseline compared with the placebo group.
In the overall population and within patient subgroups de-
fined by baseline TG, treatment with ERN/LRPT signifi-
cantly reduced LDL-C, non-HDL-C and apoB versus
placebo at Week 12 (Fig. 1). Similar placebo-adjusted reduc-
tions of approximately 17, 19 and 17 % were observed for
LDL-C, non-HDL-C and apoB, respectively, following treat-
ment with ERN/LRPT in the overall population. The
placebo-adjusted decreases in LDL-C, non-HDL-C and
apoB were numerically, but not significantly, smaller with
ERN/LRPT in the higher versus lower TG subgroup.
Table 1 Baseline characteristics by treatment group
Parameter ERN/LRPT Placebo
(N = 393) (N = 323)









Age, mean ± SD, y 61.80 ± 9.29 62.08 ± 9.27 60.58 ± 9.36 61.77 ± 9.43 62.04 ± 9.33 60.09 ± 9.99
Age, median (range), y 63 (31–79) 63 (33–79) 61 (31–76) 63 (21–80) 63 (21–80) 63 (36–77)
Sex, no. (%)
Male 233 (59.3) 187 (58.4) 46 (63.0) 208 (64.4) 182 (65.2) 26 (59.1)
Female 160 (40.7) 133 (41.6) 27 (37.0) 115 (35.6) 97 (34.8) 18 (40.9)
Population subgroups, no. (%)a
Statin-treated 310 (78.9) 259 (80.9) 51 (69.9) 259 (80.2) 227 (81.4) 32 (72.7)
Other LMT-treated 33 (8.4) 24 (7.5) 9 (12.3) 34 (10.5) 28 (10.0) 6 (13.6)
Drug naive 72 (18.3) 54 (16.9) 18 (24.7) 55 (17.0) 47 (16.8) 8 (18.2)
BMI, mean ± SD, kg/m2 31.28 ± 6.45 30.90 ± 6.43 32.93 ± 6.34 30.48 ± 5.83 30.26 ± 5.92 31.84 ± 5.01
Baseline values, mean ± SD
apoB, g/L 0.93 ± 0.19 0.90 ± 0.17 1.1 ± 0.18 0.91 ± 0.17 0.89 ± 0.15 1.1 ± 0.20
TC, mmol/L 4.30 ± 0.68 4.20 ± 0.67 4.69 ± 0.58 4.21 ± 0.64 4.14 ± 0.60 4.65 ± 0.75
Non-HDL-C, mmol/L 3.00 ± 0.64 2.85 ± 0.57 3.64 ± 0.54 2.91 ± 0.58 2.81 ± 0.50 3.53 ± 0.64
HDL-C, mmol/L 1.29 ± 0.36 1.35 ± 0.35 1.04 ± 0.25 1.30 ± 0.34 1.33 ± 0.35 1.12 ± 0.25
LDL-C, mmol/L 2.26 ± 0.53 2.26 ± 0.53 2.27 ± 0.55 2.20 ± 0.47 2.19 ± 0.44 2.27 ± 0.61
TGb, mmol/L 1.42 (0.36–7.10) 1.27 (0.36–2.23) 2.88 (2.28–7.10) 1.45 (0.44–5.75) 1.32 (0.44–2.24) 2.63(2.26–5.75)
CRPb, mg/L 1.8 (0.1–56.2) 1.7 (0.1–56.2) 2.3 (0.3–36.3) 1.5 (0.1–69.7) 1.5 (0.1–69.7) 1.40 (0.3–15.7)
FPG, mmol/L 7.29 ± 1.81 7.10 ± 1.63 8.11 ± 2.28 7.41 ± 1.79 7.38 ± 1.83 7.62 ± 1.59
HbA1c, % 6.91 ± 0.72 6.86 ± 0.69 7.11 ± 0.81 6.90 ± 0.70 6.89 ± 0.69 6.97 ± 0.74
ApoB apolipoprotein B; BMI body mass index; ERN/LRPT ER niacin/laropiprant; HDL-C high-density lipoprotein cholesterol; LDL-C low-density lipoprotein cholesterol;
TC total cholesterol; TG triglyceride; CRP C-reactive protein; FPG fasting plasma glucose; HbA1c hemoglobin A1c
aBecause a patient can be taking both a statin and another LMT at baseline, the total percentage may be greater than 100 %
bExpressed as median
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Strong positive correlations between apoB:LDL-C and
apoB:non-HDL-C were observed at baseline and follow-
ing treatment with ERN/LRPT or placebo, irrespective
of baseline TG level (Table 2; Figs. 2 and 3). Compared
with LDL-C, non-HDL-C was more highly correlated
with apoB at baseline and Week 12 in the overall popu-
lation and in both patient subgroups defined by baseline
TG. Treatment with ERN/LRPT increased the strength
of the correlations between apoB and LDL-C in the
overall group and tended to increase the correlations in
both lower and high TG groups. ERN/LRPT produced
less pronounced increases in the correlations between
apoB and non-HDL-C, although the on-treatment corre-
lations were higher than those for apoB and LDL-C
(Table 2; Figs. 2 and 3). The improvements in the
apoB:LDL-C and apoB:non-HDL-C correlations with
ERN/LRPT treatment tended to be greater in the over-
all population and in the higher versus the lower TG
subgroup. The correlations between apoB:LDL-C and
apoB:non-HDL-C were generally similar at baseline and
study end in the placebo group for the overall popula-
tion and within both TG subgroups.
At baseline and Week 12, the predicted LDL-C and
non-HDL-C values for known apoB values were below
the targets of 2.59 mmol/L and 3.36 mmol/L, respectively
(Table 2). When the regression analyses were examined by
baseline TG level, the predicted LDL-C values were
significantly lower in the high TG versus the low TG
subgroup (i.e., 95 % CIs did not overlap) at baseline
and Week 12. This finding was observed in both treat-
ment groups, except in the placebo group at Week 12.
In contrast, the predicted non-HDL-C values were sig-
nificantly greater in the higher versus the lower TG
subgroup at baseline, but not at Week 12.
Weighted kappa statistics to assess the degree of con-
cordance between apoB:LDL-C and apoB:non-HDL-C
before and after treatment with ERN/LRPT or placebo
are presented in Table 3. A kappa value of 1 represents
perfect overlap and a value of 0 represents a complete
lack of overlap between 2 parameters. In general, the
correlations assessed by Pearson correlation coefficients
were corroborated with those assessed by the weighted
kappa. For apoB:LDL-C and apoB:non-HDL-C, the weighted
kappa values were generally similar between the treatment
groups and TG subgroups at baseline. For both treatment
groups and both TG subgroups, the weighted kappa values
were higher for the comparison of apoB:non-HDL-C versus
apoB:LDL-C at baseline and at study end. At baseline, the
degree of concordance between apoB and LDL-C was mod-
erate, while the degree of concordance between apoB and
non-HDL-C was more substantial. At Week 12, treatment
with ERN/LRPT generally increased the level of concordance
more between apoB and LDL-C than between apoB and
non-HDL-C relative to baseline and placebo.
Placebo-Subtracted Difference of LS Mean Percent Change





TG < 2.26 mmol/L
Overall
TG < 2.26 mmol/L
Overall
TG < 2.26 mmol/L
Fig. 1 Between-group differences (with 95 % confidence interval) in least square (LS) mean percentage changes from baseline at Week 12 in
LDL-C, non-HDL-C and apoB for the overall population and patient subgroups defined by baseline triglyceride (TG) value (i.e., < and ≥2.26 mmol/L)
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Table 2 Slope, intercept, Pearson correlation coefficient, and predicted LDL-C and non-HDL-C values based on simple linear
regression of LDL-C or non-HDL-C on apoB at baseline (i.e., prior to receiving randomized treatment) and Week 12
Treatment Group Na Slope Intercept apoB vs LDL-C
Pearson Correlation
Coefficient (95 % CI) [R2]
Predictedb
LDL-C Value (95 % CI)
given apoB of 0.8 g/L
Predictedb
LDL-C Value (95 % CI)
given apoB of 0.9 g/L
Baseline (i.e., pre-treatment measurement)
Pooled across treatment groups 721 2.04 0.36 0.72 (069, 0.76) [0.53] 1.98 (1.95, 2.01) 2.18 (2.16, 2.21)
TG <2.26 mmol/L 602 2.35 0.13 0.77 (0.74, 0.80) [0.59] 2.01 (1.98, 2.04) 2.24 (2.22, 2.27)
TG ≥2.26 mmol/L 119 2.35 −0.27 0.78 (0.70, 0.84) [0.61] 1.61 (1.50, 1.73) 1.85 (1.76, 1.93)
ERN/LRPT 395 2.04 0.35 0.73 (0.68, 0.77) [0.53] 1.99 (1.94, 2.03) 2.19 (2.15, 2.23)
TG <2.26 mmol/L 322 2.43 0.07 0.80 (0.75, 0.83) [0.64] 2.02 (1.98, 2.06) 2.26 (2.23, 2.30)
TG ≥2.26 mmol/L 73 2.22 −0.16 0.74 (0.61, 0.83) [0.55] 1.63 (1.47, 1.79) 1.85 (1.73, 1.98)
Placebo 326 1.99 0.38 0.72 (0.66, 0.76) [0.51] 1.98 (1.93, 2.02) 2.18 (2.14, 2.21)
TG <2.26 mmol/L 280 2.20 0.23 0.72 (0.66, 0.78) [0.53] 2.00 (1.96, 2.04) 2.22 (2.18, 2.26)
TG ≥2.26 mmol/L 46 2.51 −0.41 0.85 (0.73, 0.91) [0.72] 1.59 (1.43, 1.75) 1.84 (1.71, 1.97)
Week 12
ERN/LRPT 394 2.30 0.04 0.82 (0.79, 0.85) [0.68] 1.88 (1.84, 1.91) 2.11 (2.07, 2.15)
TG <2.26 mmol/L 321 2.61 −0.16 0.84 (0.80, 0.87) [0.70] 1.93 (1.90, 1.97) 2.20 (2.15, 2.24)
TG ≥2.26 mmol/L 73 1.99 0.13 0.86 (0.78, 0.91) [0.74] 1.73 (1.65, 1.81) 1.93 (1.86, 2.00)
Placebo 323 2.09 0.27 0.73 (0.68, 0.78) [0.54] 1.94 (1.89, 1.98) 2.14 (2.07, 2.15)
TG <2.26 mmol/L 279 2.35 0.06 0.77 (0.71, 0.81) [0.59] 1.94 (1.89, 1.98) 2.17 (2.13, 2.21)
TG ≥2.26 mmol/L 44 1.68 0.50 0.69 (0.49, 0.82) [0.47] 1.84 (1.66, 2.02) 2.01 (1.86, 2.15)
Treatment Group Na Slope Intercept apoB vs non-HDL-C
Pearson Correlation
Coefficient (95 % CI) [R2]
Predictedb
Non-HDL-C Value
(95 % CI) given
apoB of 0.8 g/L
Predictedb
Non-HDL-C Value
(95 % CI) given
apoB of 0.9 g/L
Baseline (i.e., pre-treatment measurement)
Pooled across treatment groups 721 2.97 0.21 0.87 (0.85, 0.89) [0.76] 2.59 (2.56, 2.62) 2.89 (2.87, 2.91)
TG <2.26 mmol/L 602 2.82 0.31 0.84 (0.82, 0.87) [0.71] 2.57 (2.54, 2.60) 2.85 (2.83, 2.88)
TG ≥2.26 mmol/L 119 2.59 0.81 0.85 (0.79, 0.89) [0.72] 2.88 (2.78, 2.98) 3.14 (3.06, 3.21)
ERN/LRPT 395 2.95 0.25 0.87 (0.85, 0.89) [0.76] 2.61 (2.57, 2.65) 2.90 (2.87, 2.94)
TG <2.26 mmol/L 322 2.82 0.32 0.86 (0.83, 0.89) [0.74] 2.58 (2.54, 2.61) 2.86 (2.83, 2.89)
TG ≥2.26 mmol/L 73 2.38 1.07 0.81 (0.71, 0.87) [0.65] 2.97 (2.83, 3.10) 3.20 (3.10, 3.31)
Placebo 326 3.00 0.17 0.87 (0.84, 0.89) [0.75] 2.57 (2.53, 2.61) 2.87(2.84, 2.90)
TG <2.26 mmol/L 280 2.82 0.30 0.82 (0.78, 0.86) [0.67] 2.56 (2.52, 2.60) 2.84 (2.81, 2.88)
TG ≥2.26 mmol/L 46 2.87 0.46 0.91 (0.83, 0.95) [0.82] 2.76 (2.62, 2.90) 3.05 (2.94, 3.15)
Week 12
ERN/LRPT 394 3.28 -0.13 0.89 (0.87, 0.91) [0.79] 2.49 (2.45, 2.53) 2.82 (2.78, 2.86)
TG <2.26 mmol/L 321 3.15 -0.06 0.87 (0.84, 0.90) [0.76] 2.47 (2.43, 2.51) 2.78 (2.74, 2.83)
TG ≥2.26 mmol/L 73 3.36 -0.12 0.88 (0.82, 0.92) [0.78] 2.56 (2.44, 2.68) 2.89 (2.78, 3.00)
Placebo 323 3.21 -0.04 0.87 (0.84, 0.90) [0.76] 2.52 (2.48, 2.56) 2.84 (2.80, 2.88)
TG <2.26 mmol/L 279 3.00 0.12 0.85 (0.82, 0.88) [0.73] 2.52 (2.48, 2.57) 2.82 (2.79, 2.86)
TG ≥2.26 mmol/L 44 3.60 -0.33 0.89 (0.79, 0.93) [0.78] 2.55 (2.35, 2.75) 2.91 (2.75, 3.07)
apoB apolipoprotein B; LDL-C low-density lipoprotein cholesterol; HDL-C high-density lipoprotein cholesterol; ERN/LRPT niacin/lariproprant; TG triglyceride
aNumber of patients with paired apoB and LDL-C or non-HDL-C measurements
bPredicted LDL-C or non-HDL-C value (mmol/L) assuming apoB value of 0.8 or 0.9 g/L
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Discussion
The influence of statin therapy on the correlations be-
tween apoB:LDL-C and apoB:non-HDL-C in dyslipidemic
patients has been well studied [30–34]. Statin therapy
produces smaller percentage reductions in apoB than in
LDL-C and non-HDL-C. Further, statin therapy strengthens
the linear relationships between apoB:LDL-C and apoB:
non-HDL-C, as evidenced by increases in the correlation
coefficients and kappa values (i.e., a measure of the degree
of concordance between 2 parameters) for these parameters
in statin-treated versus untreated patients. Although
the influence of non-statin lipid-modifying drugs on
the linear relationships between these lipid/lipoprotein
parameters has been less well studied, a recent analysis
evaluated the effects of ERN/LRPT, simvastatin (SIMVA),
and ERN/LRPT + SIMVA on apoB:LDL-C and apoB:
non–HDL-C correlations in patients with dyslipidemia
[35]. The results demonstrated that both LDL-C and
non–HDL-C were well correlated with apoB at baseline
and following treatment with ERN/LRPT, SIMVA and
the combination of both, and the correlations were
higher and the predicted LDL-C and non–HDL-C
levels based on apoB were considerably lower compared
with baseline [35].
The primary purpose of the present analysis was to
examine the effects of ERN/LRPT on the relationships
(i.e., correlation coefficients, linear regression analyses and
kappa values) between apoB:LDL-C and apoB:non-HDL-C
in patients with T2DM. At baseline, approximately
78 % of patients were receiving statin-based (non-niacin)
lipid-modifying therapy and were permitted to continue
these medications throughout the study. Thus, these ana-
lyses examine the effects of ERN/LRPT on relationships
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Fig. 2 Scatterplots of apoB versus LDL-C at baseline (a) and follow-
ing treatment with ERN/LRPT or placebo for 12 weeks (b). The upper
thresholds for the less-stringent LDL-C <100 mg/dL and apoB
<90 mg/dL goals are denoted by horizontal and vertical lines, re-
spectively. Right lower quadrant shows the large number of subjects
who met LDL-C goal <100 mg/dL but did not reach apoB goal
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Fig. 3 Scatterplots of apoB versus non-HDL-C at baseline (a) and fol-
lowing treatment with ERN/LRPT or placebo at Week 12 (b). The
upper thresholds for the less-stringent non-HDL-C <130 mg/dL and
apoB <90 mg/dL goals are denoted by horizontal and vertical lines,
respectively. Right lower quadrant shows the large number of sub-
jects who met non-HDL-C goal <130 mg/dL but did not reach apoB
goal <90 mg/dL after niacin treatment
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patients, the majority of whom were taking a statin-based
therapy. Given the known influence of TG levels on LDL
particle composition, the relationships between these
lipid/lipoprotein parameters were also examined at base-
line and following treatment in subgroups of patients with
lower and higher baseline TG values.
Treatment with ERN/LRPT produced similar magnitude
reductions from baseline in apoB, LDL-C and non-HDL-C
in patients with T2DM (i.e., mean reductions ranging from
17 to 19 % across the lipid/lipoprotein parameters). A
trend toward smaller magnitude reductions in apoB,
LDL-C and non-HDL-C were observed in patients with
higher versus lower baseline TG values (> and <2.26 mmol/L).
Nevertheless, similar magnitude mean percent reduc-
tions from baseline in apoB, LDL-C and non-HDL-C
were observed when the treatment effects were examined
separately within each of the TG subgroups. Overall, the
findings of the current study support prior study results,
showing that treatment with ERN/LRPT and ERN (with-
out LRPT) produces somewhat comparable reductions in
apoB, LDL-C and non-HDL-C in patients with dyslipidemia
[38]. This study, for the first time, extends these find-
ings to include patients with T2DM, irrespective of
baseline TG level. In contrast, studies of statin mono-
therapy show significantly larger magnitude reductions
in LDL-C and non-HDL-C versus apoB in a wide variety
of patient populations, including those with T2DM
and hypertriglyceridemia [19, 28]. The differential effects
of ERN compared with statins on apoB, LDL-C and
non-HDL-C are likely due to differences in the mecha-
nisms of actions of these agents.
This analysis demonstrated strong, linear relationships
between apoB:LDL-C and apoB:non-HDL-C, both at base-
line and following treatment with ERN/LRPT. Treatment
with ERN/LRPT increased the strengths of the correlation
coefficients between apoB:LDL-C, with a less pronounced
effect on apoB:non-HDL-C. The strengths of the corre-
lations between apoB:LDL-C and apoB:non-HDL-C were
generally stronger in the higher versus the lower TG
subgroup.
Table 3 Degree of concordance among apoB, LDL-C, and non-HDL-C levels at baseline and study endpoint in the pooled treatment
groups for the overall population and treatment subgroups defined by baseline TG < and ≥2.26 mmol/L
N Concordance between apoB and LDL-C N Concordance between apoB and Non-HDL-C
Weighted kappaa (95 % CI) Weighted kappaa (95 % CI)
Baseline (i.e., drug-naïve patients)
Overall Population
All Treatments 716 0.49 (0.44, 0.53) 716 0.66 (0.62, 0.69)
TG <2.26 mmol/L 599 0.52 (0.47, 0.56) 599 0.63 (0.60, 0.67)
TG ≥2.26 mmol/L 117 0.56 (0.46, 0.65) 117 0.64 (0.56, 0.72)
ERN/LRPT 393 0.50 (0.45, 0.56) 393 0.67 (0.63, 0.72)
TG <2.26 mmol/L 320 0.54 (0.49, 0.60) 320 0.65 (0.60, 0.70)
TG ≥2.26 mmol/L 73 0.56 (0.44, 0.68) 73 0.65 (0.56, 0.75)
Placebo 323 0.46 (0.40, 0.53) 323 0.65 (0.60, 0.70)
TG <2.26 mmol/L 279 0.50 (0.43, 0.57) 279 0.64 (0.58, 0.69)
TG ≥2.26 mmol/L 44 0.55 (0.39, 0.71) 44 0.71 (0.56, 0.85)
Endpoint (i.e., following randomized treatment)
Overall Population
All Treatments 716 0.61 (0.57, 0.64) 716 0.73 (0.70, 0.76)
TG <2.26 mmol/L 599 0.64 (0.60, 0.68) 599 0.73 (0.70, 0.76)
TG ≥2.26 mmol/L 117 0.57 (0.47, 0.67) 117 0.70 (0.63, 0.78)
ERN/LRPT 393 0.64 (0.60, 0.69) 393 0.73 (0.69, 0.77)
TG <2.26 mmol/L 320 0.66 (0.61, 0.71) 320 0.72 (0.67, 0.76)
TG ≥2.26 mmol/L 73 0.64 (0.54, 0.75) 73 0.71 (0.60, 0.82)
Placebo 323 0.53 (0.46, 0.59) 323 0.65 (0.60, 0.71)
TG <2.26 mmol/L 279 0.55 (0.49, 0.62) 279 0.66 (0.61, 0.72)
TG ≥2.26 mmol/L 44 0.53 (0.38, 0.69) 44 0.68 (0.56, 0.81)
ERN/LRPT niacin/laropiprant; apoB apolipoprotein B DL-C low-density lipoprotein cholesterol; HDL-C high-density lipoprotein cholesterol; TG triglyceride
aThe k statistic, on a scale from 0 to 1, reflects the degree of agreement between two variables. The levels of agreement range from slight (0–0.20), fair (0.21–0.40),
moderate (0.41–0.60), substantial (0.61–0.80), and almost perfect (0.81–1.00)
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For the overall population, the predicted LDL-C and
non-HDL-C levels corresponding to known apoB
values at baseline were already below the targets of
2.59 mmol/L and 3.36 mmol/L, respectively, and these
levels were further lowered following treatment with
ERN/LRPT. When examined by TG subgroup, the pre-
dicted LDL-C values were lower in the higher TG versus
the lower TG subgroup, both at baseline and study end-
point. Conversely, the predicted non-HDL-C values were
higher in the high TG versus the lower TG subgroup at
baseline, but this finding was less pronounced at study
endpoint.
ApoB was more concordant with non-HDL-C than with
LDL-C, both at baseline and study endpoint, irrespective
of the TG subgroup. This was expected since apoB is a
measure of the number of non-HDL particles. Treat-
ment with ERN/LRPT increased the concordance between
apoB:non-HDL-C less than that between apoB:LDL-C,
although the former remained higher than the latter.
Conclusion
In conclusion, the apoB:LDL-C and apoB:non–HDL-C
correlation coefficients and kappa values were higher and
the predicted LDL-C and non–HDL-C levels for a known
apoB value were lower following treatment with ERN/LRPT
compared with baseline levels. Interestingly, this was despite
the fact that there were greater percent decreases in LDL-C
and non-HDL-C than in apoB. Although some discordance
remains between non-HDL-C and apoB levels, these data
suggest that there may be only modest benefit from
measurement of apoB in addition to the non-HDL-C
level available as part of the standard lipid panel. These
data also show the attainment of more aggressive LDL-C
and non-HDL-C goals in patients receiving ERN in com-
bination with a statin, reminding of the potential of com-
bination lipid-modifying therapy for further reduction of
coronary risk by helping to normalize apoB-containing
atherogenic lipoprotein composition and levels.
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